La chaîne d'options affiche les données clés des options sur actions de Capri Holdings à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Capri Holdings..

Capri Holdings (NYSE:CPRI) Stock, Chaîne d'Options

Capri Holdings

Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Michael Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. In April 2025, Capri agreed to sell Versace to Prada. John Idol has served as Capri's CEO since 2003.

Capri Holdings Ltd

<p>Barclays  analyst Adrienne Yih   maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Overweight and lowers the price target from $33 to $32.</p>


News

Price Target

Analyst Ratings

Barclays Maintains Overweight on Gap, Lowers Price Target to $32

<p>Barclays  analyst Mark Devries   maintains SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) with a Overweight and raises the price target from $34 to $38.</p>


Barclays Maintains Overweight on SLM, Raises Price Target to $38

<p>Piper Sandler  analyst Harsh Kumar   reiterates Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Overweight and lowers the price target from $95 to $85.</p>


Reiteration

MRVL

Piper Sandler Reiterates Overweight on Marvell Tech, Lowers Price Target to $85

<p><a href="https://www.bloomberg.com/news/articles/2025-05-30/brookfield-eyes-3-billion-in-debt-for-colonial-pipeline?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-30/brookfield-eyes-3-billion-in-debt-for-colonial-pipeline?embedded-checkout=true</a></p>


General

'Brookfield Eyes $3 Billion in Debt for Colonial Pipeline'- Bloomberg

WIIM

Cooper Companies shares are trading lower despite a Q2 earnings beat. JP Morgan downgraded the stock from Overweight to Neutral and lowered its price target from $110 to $76 following the report.

<p>Barclays  analyst Tim Long   maintains NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) with a Overweight and raises the price target from $115 to $117.</p>


NTAP

Barclays Maintains Overweight on NetApp, Raises Price Target to $117

<p>Piper Sandler  analyst Rob Owens   maintains Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) with a Overweight and lowers the price target from $135 to $120.</p>


ESTC

Piper Sandler Maintains Overweight on Elastic, Lowers Price Target to $120

<p>Barclays  analyst Nicholas Campanella   maintains Evergy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVRG#NASDAQ">EVRG</a>) with a Overweight and lowers the price target from $73 to $71.</p>


EVRG

Barclays Maintains Overweight on Evergy, Lowers Price Target to $71

<p>Piper Sandler  analyst Jason Bednar   reiterates Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) with a Overweight and lowers the price target from $115 to $105.</p>


Piper Sandler Reiterates Overweight on Cooper Companies, Lowers Price Target to $105

<p>Barclays  analyst Raimo Lenschow   maintains Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) with a Overweight and lowers the price target from $124 to $105.</p>


Barclays Maintains Overweight on Elastic, Lowers Price Target to $105

<p>Piper Sandler  analyst Paul Newsome   maintains Palomar Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLMR#NASDAQ">PLMR</a>) with a Overweight and raises the price target from $171 to $177.</p>


PLMR

Piper Sandler Maintains Overweight on Palomar Hldgs, Raises Price Target to $177

<p><a href="https://www.wsj.com/finance/banking/hsbc-retreats-from-banking-smaller-u-s-businesses-d728866f" title="https://www.wsj.com/finance/banking/hsbc-retreats-from-banking-smaller-u-s-businesses-d728866f">https://www.wsj.com/finance/banking/hsbc-retreats-from-banking-smaller-u-s-businesses-d728866f</a></p>


HSBC

'HSBC Retreats From Banking Smaller U.S. Businesses; Chief Executive Georges Elhedery has recently scaled back HSBC's offering in investment banking' - WSJ

<p>Barclays  analyst Tim Long   maintains Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) with a Equal-Weight and raises the price target from $116 to $123.</p>


DELL

Barclays Maintains Equal-Weight on Dell Technologies, Raises Price Target to $123

<p>Piper Sandler  analyst Korinne Wolfmeyer   reiterates Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Neutral and raises the price target from $386 to $437.</p>


ULTA

Piper Sandler Reiterates Neutral on Ulta Beauty, Raises Price Target to $437

<p>Barclays  analyst Brian Morton   maintains Canadian Imperial Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CM#TSX">CM</a>) with a Underweight and raises the price target from C$88 to C$90.</p>


TSX:CM

Barclays Maintains Underweight on Canadian Imperial Bank, Raises Price Target to C$90

<p>American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) has outperformed the market over the past 20 years by 4.64% on an annualized basis producing an average annual return of 12.9%. Currently, American Tower has a market capitalization of $99.48 billion. </p>
<p><strong>Buying $100 In AMT:</strong> If an investor had bought $100 of AMT stock 20 years ago, it would be worth <strong>$1,151.67</strong> today based on a price of $212.50 for AMT at the time of writing.</p>
<h3>American Tower's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748621714_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

<p>Piper Sandler  analyst Peter Keith   maintains Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) with a Overweight and lowers the price target from $92 to $82.</p>


Piper Sandler Maintains Overweight on Best Buy Co, Lowers Price Target to $82

<p><strong>Lucid Group Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) shares are under pressure Friday morning, down 5.39% to $2.28. Despite no company-specific news, the sell-off mirrors a sector-wide downturn in EV stocks triggered by recent political developments.</p>
<p><strong>What To Know:</strong> Investor sentiment across the EV market has soured following the <a href="https://www.benzinga.com/25/05/45586258/is-trumps-big-beautiful-bill-a-major-roadblock-for-elon-musks-tesla-and-other-evs">passage</a> of former President <strong>Donald Trump's</strong> "Big Beautiful Bill" in the Republican-controlled House. The bill proposes sweeping changes, including the elimination of the $7,500 federal EV tax credit for automakers exceeding 200,000 U.S. sales by the end of 2025. </p>
<p>It also introduces new annual EV fees and rolls back several clean energy incentives. These proposed policy shifts have raised fears about long-term <a href="https://www.benzinga.com/25/05/45586258/is-trumps-big-beautiful-bill-a-major-roadblock-for-elon-musks-tesla-and-other-evs">demand</a> and growth prospects across the EV industry.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/cannabis/25/05/45698612/hp-stock-drops-10-post-earnings-miss-outlook-disappoints">HP Stock Drops 10% Post-Earnings Miss, Outlook Disappoints</a></strong></p>
<p>Trading activity in Lucid shares is notably elevated, with session volume already reaching 116.68 million shares, surpassing the 100-day average volume of 112.14 million, even though it's only Friday morning.</p>
<p>Additionally, Lucid's short interest remains substantial. Approximately 369.87 million shares are sold short, representing 45.4% of the float, signaling continued bearish sentiment among investors.</p>
<p>Lucid is not alone in its decline. Shares of fellow EV manufacturer <strong>Rivian Automotive Inc</strong> and others have also come under pressure as the sector adjusts to the potential implications of recent legislation.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/cannabis/25/05/45695750/sharplink-gaming-sbet-stock-soars-over-2600-in-a-week-on-ethereum-treasury-deal">SharpLink Gaming Stock Soars Over 2,600% In A Week On Ethereum Treasury Deal</a></strong></p>
<h2 class="wp-block-heading">How To Buy LCID Stock</h2>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in Lucid Group&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, LCID has a 52-week high of $4.43 and a 52-week low of $1.93.</p>
<p><em>Image: Courtesy of Lucid</em></p>


LCID

Lucid Group Stock Drops Amid Broader EV Sector Headwinds: What's Going On?

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>JD.com</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with JD, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 8 uncommon options trades for JD.com.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 12% bullish and 75%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $97,593, and 5 are calls, for a total amount of $150,870.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $30.0 to $37.5 for JD.com during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of JD.com stands at 3630.0, with a total volume reaching 2,341.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in JD.com, situated within the strike price corridor from $30.0 to $37.5, throughout the last 30 days.</p>
<h3>JD.com Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748621631_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>JD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$0.44</td>
<td>$0.43</td>
<td>$0.43</td>
<td>$30.50</td>
<td>$37.5K</td>
<td>77</td>
<td align="right">874</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$3.45</td>
<td>$3.35</td>
<td>$3.4</td>
<td>$30.00</td>
<td>$34.0K</td>
<td>2.1K</td>
<td align="right">51</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.17</td>
<td>$1.15</td>
<td>$1.17</td>
<td>$32.50</td>
<td>$30.6K</td>
<td>11.3K</td>
<td align="right">262</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$1.63</td>
<td>$1.52</td>
<td>$1.53</td>
<td>$31.00</td>
<td>$30.6K</td>
<td>290</td>
<td align="right">200</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.03</td>
<td>$37.50</td>
<td>$30.2K</td>
<td>5.3K</td>
<td align="right">112</td>
</tr>
</tbody>
</table>
</p>
<h3>About JD.com</h3>
<p>JD.com is the third-largest Chinese e-commerce platform by GMV in 2024. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.</p>
<p>Having examined the options trading patterns of JD.com, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of JD.com</h3>
<ul>
<li>Trading volume stands at 4,533,479, with JD's price down by -1.44%, positioned at $32.47.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 76 days.</li>
</ul>
<h3>What The Experts Say On JD.com</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $45.75.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Benchmark continues to hold a Buy rating for JD.com, targeting a price of $53.<br />
&#x2A; An analyst from Susquehanna persists with their Neutral rating on JD.com, maintaining a target price of $40.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on JD.com with a target price of $42.<br />
&#x2A; An analyst from Mizuho persists with their Outperform rating on JD.com, maintaining a target price of $48. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for JD.com with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

Behind the Scenes of JD.com's Latest Options Trends

<p>Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) revealed 43 unusual trades.</p>
<p>Delving into the details, we found 16% of traders were bullish, while 53% showed bearish tendencies. Out of all the trades we spotted, 18 were puts, with a value of $1,266,325, and 25 were calls, valued at $1,321,692.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $300.0 to $600.0 for Regeneron Pharmaceuticals over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Regeneron Pharmaceuticals stands at 154.61, with a total volume reaching 1,184.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Regeneron Pharmaceuticals, situated within the strike price corridor from $300.0 to $600.0, throughout the last 30 days.</p>
<h3>Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748621626_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$43.9</td>
<td>$41.6</td>
<td>$43.9</td>
<td>$540.00</td>
<td>$237.0K</td>
<td align="right">133</td>
<td align="right">58</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$83.9</td>
<td>$80.0</td>
<td>$80.0</td>
<td>$575.00</td>
<td>$192.0K</td>
<td align="right">46</td>
<td align="right">30</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$43.8</td>
<td>$41.7</td>
<td>$43.8</td>
<td>$540.00</td>
<td>$170.8K</td>
<td align="right">133</td>
<td align="right">104</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$268.3</td>
<td>$229.4</td>
<td>$249.8</td>
<td>$300.00</td>
<td>$124.9K</td>
<td align="right">2</td>
<td align="right">5</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$33.8</td>
<td>$30.4</td>
<td>$31.5</td>
<td>$500.00</td>
<td>$110.2K</td>
<td align="right">0</td>
<td align="right">47</td>
</tr>
</tbody>
</table>
</p>
<h3>About Regeneron Pharmaceuticals</h3>
<p>Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).</p>
<p>In light of the recent options history for Regeneron Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Regeneron Pharmaceuticals</h3>
<ul>
<li>With a trading volume of 3,313,559, the price of REGN is down by -18.78%, reaching $491.69.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 62 days from now.</li>
</ul>
<h3>What The Experts Say On Regeneron Pharmaceuticals</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $817.67.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $943.<br />
&#x2A; An analyst from Guggenheim has decided to maintain their Buy rating on Regeneron Pharmaceuticals, which currently sits at a price target of $810.<br />
&#x2A; In a positive move, an analyst from Citigroup has upgraded their rating to Buy and adjusted the price target to $700. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Regeneron Pharmaceuticals with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Comments

Capri Holdings

Capri Holdings (CPRI) Options

Capri Holdings (NYSE:CPRI) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL